PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

	Complete if Known						
Application Number		09/498,046					
	Filing Date	February 4, 2000					
	First Named Inventor	Sabine Neirynck					
	Prior Art Unit	1648					
	Examiner Name	Stacy Brown Chen					
	Attorney Docket Number	VIB-103.0 (1796/97843)					

<b>J</b>	U.S. PATENT DOCUMENTS											
xaminer Initials*	Cite No.1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear							
	E1	5,871,747	2-16-1999	Gengoux-Sedlik et al. (English)								

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>			
	E2	WO 94/06472	31 March 1994	Gengoux et al(Femish)					
	E3	AU 49273 90	09 Aug 1990	Highfield et al.					
	E4	WO 98/23735	04 June 1998	Mizzen et al.					
	1					T			

		OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ6					
	E5	Opposition Letter dated Sept. 4, 2006 to European Patent No. EP 0 996 717 B1						
·····	E6	Notice of Opposition to European Patent No. EP 0 996 717 B1 dated Sept. 5, 2006						
,	E7	Opposition Letter dated Sept. 5, 2006 to European Patent No. EP 0 996 717 B1	1					
	E8	Opposition Letter dated Sept. 7, 2006 to European Patent No. EP 0 996 717 B1						
	E9	Slepushkin et al., Vaccine, Vol. 13, No. 15, pp 1399-1402,1995 "Protection of Mice Against Influenza a Virus Challenge by Vaccination with Baculovirus-Expressed M2 Protein"						
	E10	Pouwels et al., Journal of Biotechnology 44 (1996) 183-192 "The Potential of Lactobacillus as a Carrier for Oral Immunization: Development and Preliminary Characterization of Vector Systems for Targeted Delivery of Antigens"						
	E11A	(English version) Insertie Van Nucleoproteïne T-Cel Epitoop Van Het Influenza A Virus in Het M2-Hepatltis B Core Fusie-Eiwit, by Bart Bamps, Promotor: Professor Willy Min Jou, Begeleider: Sabine Neirynck, Laboratorium voor Moleculaire Biologie VIB, Universiteit GENT, Academiejaar 1996-1997, Academic Degree obtained July 2, 1997	7					
	E11B	(Femish version) Insertie Van Nucleoproteïne T-Cel Epitoop Van Het Influenza A Virus in Het M2- Hepatltis B Core Fusie-Eiwit, by Bart Bamps, Promotor: Professor Willy Min Jou, Begeleider: Sabine Neirynck, Laboratorium voor Moleculaire Biologie VIB, Universiteit GENT, Academiejaar 1996- 1997, Academic Degree obtained July 2, 1997						

Examiner	,	Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST .16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W8	K Substitute for Form PTO-SI	B/08A, wh	ich is a US PTO	Complete if Known		
	orm 1449A/PTO and 1449B/P			Application Number	09/498,046	
INFOR	RMATION D	ISCI	OSURE	Filing Date	February 4, 2000	
				First Named Inventor	Sabine Neirynck	
STATEMENT BY APPLICANT				Prior Art Unit	1648	
(use as many sheets as necessary)			necessary)	Examiner Name	Stacy Brown Chen	
Sheet	2	of	3	Attorney Docket Number	VIB-103.0 (1796/97843)	

E	E	English version) Een Expressieplasmide Leidend Tot De Presentatie Van Influenza M2 iwitepitopen Op Het E. Coli Celoppervlak, by Sabine Neirynck, Promotor: Professor W. Fiers, aboratorium voor Moleculaire Biologie VIB, Rijksuniversiteit GENT, Academiejaar 1987-1988, cademic Degree obtained September 30, 1988
E	12B (F E L:	Femish version) Een Expressieplasmide Leidend Tot De Presentatie Van Influenza M2 iwitepitopen Op Het E. Coli Celoppervlak, by Sabine Neirynck, Promotor: Professor W. Fiers, aboratorium voor Moleculaire Biologie VIB, Rijksuniversiteit GENT, Academiejaar 1987-1988, cademic Degree obtained September 30, 1988
E	13 La	amb, R.A. et al., "Influenza Virus M₂ Protein is an Integral Membrane Protein Expressed on the affected-Cell Surface," Cell 40:627-633 (1985);
E	F	harbit, A., et al., "Probing the Topology of a Bacterial Membrane Protein by Genetic Insertion of a oreign Epitope; Expression at the Cell Surface, " <i>EMBO J.</i> 5:3029-3037 (1986)
E	R	harbit, A., et al., Presentation of Two Epitopes of the preS2 Region of Hepatitis B Virus on Live ecombinant Bacteria, " J. Immunol., 139:1658-1664 (1987);
E	In P	rancis, M.J., et al., "Peptide Vaccines Based on Enhanced nmunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core rotein," In: Antibodies, Antigens, and Molecular Mimicry, Methods in Enzymology Vol. 178, J.J. agone, editor, pages 659-676, Academic Press, Inc., New York (1989)
E	17 B	orisova, G.P., et al., "Recombinant Core Particles of Hepatitis B Virus Exposing Foreign Antigenic leterminants on Their Surface," FEBS Letters 259: 121-124 (1989);
E	```   н	larke, B.E., et al., "Presentation and Immunogenicity of Viral Epitopes on the Surface of a Hybrid lepatitis B Virus Core Particles Produced in Bacteria," <i>J. General Virology</i> 71: 1109-1117 (1990);
E	19 F	rancis, M.J., et al., "Immunological Properties of Hepatitis B Core Antigen Fusion Proteins," Proc. latt. Acad. Sci. 87:2545-2549 (1990);
E	l P	larke, B.E., et al., "Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core rotein," Nature 330:381-384 (1987);
E		rown, A.L., et al., "Foreign Epitopes in Immunodominant Regions of Hepatitis B Core Particles are lighly Immunogenic and Conformationally Restricted," <i>Vaccine</i> 9:595-601 (1991);
E	E	on Brunn, A., et al., "Principal Neutralizing Domain of HIV-1 is Highly Immunogenic when xpressed on the Surface of Hepatitis B Core Particles," Vaccine 11:817-824 (1993);
E	(1	umpens, P., et al., "Hepatitis B Virus Core Particles as Epitope Carriers," Intervirology 38:63-74 (1995);
E	ΙE	ebedee, S.L., et al., "Characterization of the Influenza Virus M2 Integral Membrane Protein and expression at the Infected-Cell Surface from Cloned cDNA," J. Virology 56:502-511 (1985);
E	G	ebedee, S.L., et al., "Influenza A Virus M2 Protein: Monoclonal Antibody Restriction of Virus Growth and Detection of M2 in Virions," J. Virology 62(8):2762-2772 (1988);
E	lr p	atz, J.M., et al., "Immune Mechanisms of Protection Induced by Vaccination of BALB/c Mice with Influenza A Virus M2 Protein," In: Options for the Control of Influenza III, Leo Brown, et al. (eds.), ages 837-843 Elsevier, B.V., (1996)
E	В	lepushkin, V.A., et al., "Protection of Mice Against Influenza A Virus Challenge by Vaccination with aculovirus-Expressed M2 Protein," Vaccine 13:1399-1402 (1995).
H	<b>'-</b> 6   A	reanor, J.J. et al., "Passively Transferred Monoclonal Antibody to the M2 Protein Inhibits Influenza Virus Replication in Mice," <i>Journal of D5 Virology</i> , 64(3):1375-1377 (1990)
E	С	lack, R.A. et al., "Antibody Response to the M2 Protein of Influenza A Virus Expressed in Insect cells", Journal of General Virology 74:143-146 (1993)
E	Ir	longo, S. et al., "Characterization of a Second Protein (CM2) Encoded by RNA Segment 6 of full of the following of Virology 71(4):2786-2792 (Apr. 1997)
	31 N	filich, D.R. et al., "The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety", An NY Acad Sci. 754: 87-201 (1995)

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>1</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W	3K Substitute for Form PTO-S	B/08A, wh	ich is a US PTO	Complete if Known		
Substitute for f	orm 1449A/PTO and 1449B/P	то		Application Number	09/498,046	
INFO	RMATION D	ISCI	OSURF	Filing Date	February 4, 2000	
	EMENT BY			First Named Inventor	Sabine Neirynck	
SIAI	EMENI BY	APP	LICANI	Prior Art Unit	1648	
(use as many sheets as necessary)			necessary)	Examiner Name	Stacy Brown Chen	
Sheet	3	of	3	Attorney Docket Number	VIB-103.0 (1796/97843)	

E32 R. Ulrich, "Core Particles of Hepatitis B Virus as Carrier for Foreign Epitopes", Advances in Virus Research 50:141-182 (1998)  E33 Cox et al., "Identification of Sequence Changes in the Cold-Adapted, Live Attenuated Influenza Vaccine Strain, AAnn Arbor/608 (H2N2), Virology 167:554-567 (1988)  E34 Allen et al., "Influenza Virus RNA Segment 7 Has the Coding Capacity for Two Polypeptides", Virology, 107:548-551 (1980)  E35 EMBL U 202084 Reports Influenza A Virus  E36 McEwen, J. et al. (1992), "Synthetic Recombinant Vaccine Expressing Influenza Haemagglutinin Epitope in Salmonalla Flagellin Leads to Partial Protection in Mice" Vaccine, 10(6):405-411 (1992)  E37 Levi, R. and Aron, R. "Synthetic Recombinant Influenza Vaccine Induces Efficient Long-Term Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)  E38 Wells, J.M. et al. "Lactococcus Leads: High-level Expression of Tetanus Toxin Fragment C and Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)  E39 Kovacsovice-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of Exogenous Antigen Upon Phagocytosis by Macrophages" PNAS, 90:4942-4946 (1993)				
E33 Cox et al., "Identification of Sequence Changes in the Cold-Adapted, Live Attenuated Influenza Vaccine Strain, A/Ann Arbor/6/60 (H2N2), Virology 167:554-567 (1988)  E34 Allen et al., "Influenza Virus RNA Segment 7 Has the Coding Capacity for Two Polypeptides"", Virology, 107:548-551 (1980)  E35 EMBL U 02084 Reports Influenza A Virus  E36 McEwen, J. et al. (1992), "Synthetic Recombinant Vaccine Expressing Influenza Haemagglutinin Epitope in Salmonella Flagellin Leads to Partial Protection in Mice" Vaccine, 10(6):405-411 (1992)  E37 Levi, R. and Aron, R. "Synthetic Recombinant Influenza Vaccine Induces Efficient Long-Term Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)  E38 Wells, J.M. et al. "Lactococcus Lactis: High-level Expression of Tetanus Toxin Fragment C and Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)  Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of		E32	Research 50:141-182 (1998)	
E34 Allen et al., "Influenza Virus RNA Segment 7 Has the Coding Capacity for Two Polypeptides"", Virology, 107:548-551 (1980)  E35 EMBL U 02084 Reports Influenza A Virus  E36 McEwen, J. et al. (1992), "Synthetic Recombinant Vaccine Expressing Influenza Haemagglutinin Epitope in Salmonella Flagellin Leads to Partial Protection in Mice" Vaccine, 10(6):405-411 (1992)  E37 Levi, R. and Aron, R. "Synthetic Recombinant Influenza Vaccine Induces Efficient Long-Term Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)  E38 Wells, J.M. et al. "Lactococcus Lactis: High-level Expression of Tetanus Toxin Fragment C and Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)  Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of		E33	Cox et al., "Identification of Sequence Changes in the Cold-Adapted, Live Attenuated Influenza	
E35 EMBL U 02084 Reports Influenza A Virus  E36 McEwen, J. et al. (1992), "Synthetic Recombinant Vaccine Expressing Influenza Haemagglutinin Epitope in Salmonella Flagellin Leads to Partial Protection in Mice" Vaccine, 10(6):405-411 (1992)  E37 Levi, R. and Aron, R. "Synthetic Recombinant Influenza Vaccine Induces Efficient Long-Term Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)  E38 Wells, J.M. et al. "Lactococcus Lactis: High-level Expression of Tetanus Toxin Fragment C and Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)  E39 Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of	***************************************	E34	Allen et al., "Influenza Virus RNA Segment 7 Has the Coding Capacity for Two Polypeptides",	
E36 McEwen, J. et al. (1992), "Synthetic Recombinant Vaccine Expressing Influenza Haemagglutinin Epitope in Salmonella Flagellin Leads to Partial Protection in Mice" Vaccine, 10(6):405-411 (1992)  E37 Levi, R. and Aron, R. "Synthetic Recombinant Influenza Vaccine Induces Efficient Long-Term Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)  E38 Wells, J.M. et al. "Lactococcus Lactis: High-level Expression of Tetanus Toxin Fragment C and Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)  E39 Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of		E35	EMBL U 02084 Reports Influenza A Virus	
Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)  E38 Wells, J.M. et al. "Lactococcus Lactis: High-level Expression of Tetanus Toxin Fragment C and Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)  E39 Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of		E36	Epitope in Salmonella Flagellin Leads to Partial Protection in Mice" Vaccine, 10(6):405-411 (1992)	
Protection Against Lethal Challenge", <i>Molecular Microbiology</i> , 8(6):1155-1162 (1993)  E39 Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of		E37	Immunity and Cross-Strain Protection, Vaccine, 14(1):85-92 (1996)	
E39 Kovacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of Exogenous Antigen Upon Phagocytosis by Macrophages" PNAS, 90:4942-4946 (1993)		E38	Protection Against Lethal Challenge", Molecular Microbiology, 8(6):1155-1162 (1993)	
		E39	Koyacsovics-Banowski, M. et al., Efficient Major Histocompatibility Complex Class I Presentation of	
		•••••••		-
	·			
				<b></b>

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.